skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Informa pharma logo

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Pharma Intelligence Logo
Search Icon Pharma Report StoreRecommendationsProduct loginProductLogin
Global Search Configuration

The promises of gene therapy are taking a long time to be fulfilled, in part due to challenges in developing gene vectors capable of safe and efficient delivery of therapeutic genes (transgenes) into patients’ cells. Nonetheless, these challenges are being addressed in innovative ways. A variety of first-generation vectors, both viral and non-viral, have been employed in clinical trials with varying degrees of success, and the experience gained is guiding the design of next-generation vectors.

Listen to Speaker: Patricia Reilly, Vice President, Intelligence Alliances and Product Unification, explore and examine:

  • What diseases are gene therapy companies targeting?
  • Volume of clinical trials in recent years
  • Volume of gene therapy companies in recent years
  • As deal volume for partnerships between biotechs and big pharma has increased, has deal value decreased?
  • University deals and spin outs
  • Biotechs with unpartnered therapies- who are they and what are they working on?
  • Acquisitions – Volume and what deal values have increased
  • At what point in the biotechs’ life?
  • What factors may contribute to the escalating cost of acquisition?






Will reimbursement prove to be the biggest barrier as three gene therapies gain regulatory approval?

 

Learn more in the "Trends in Gene Therapy report", available to buy here

Read also

;

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Request a free demo

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.
General enquiry

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now:

Shop now